B1DX34
R$232.30
0.00%
Stock
Becton, Dickinson and Company
Official Company Name: Becton, Dickinson and Company
Stock Symbol: B1DX34
Stock Market: B3 - Bovespa
Currency: Brazilian real - BRL
B1DX34 Stock Price - 1 Year Price Evolution & Moving Averages
1 Year Return
▼-12.80%
Daily closing prices, with moving averages and volumes - Brazilian real (BRL)
Moving averages:
- — EMA20
- — SMA50
- — SMA200
Becton, Dickinson and Company Categories
United States
languages
Healthcare
languages
Medical Instruments & Supplies
Healthcare
Medical Instruments & Supplies
Company Description
Becton, Dickinson and Company, more simply known as BD, is a medical technology company. It manufactures and markets medical devices, instrument systems, reagents, and provides consulting and analytics services. Founded in 1897, BD was a pioneer of syringes that expanded to other medical supplies such as needles, catheters, and developed a range of medical, diagnostic and research devices.
B1DX34 Stock Data
| Open | R$232.30 |
| High | R$232.30 |
| Low | R$232.30 |
| Close | R$232.30 |
| Volume | 0 |
| Previous Close | R$232.30 |
| 1-Day Change | 0.00 |
| 1-Year Change | -34.09 |
| Average Daily Volume | 13 |
| 52-Week High | R$275.00 |
| 52-Week Low | R$228.20 |
Disclaimer
All information and data available on Disfold is NOT FINANCIAL ADVICE. Invest at your own risk!
Past performance is not a guarantee of future performance. Patterns tend to repeat themselves, but they don't necessarily have to.
Successful backtests on past data do not guarantee the future success of the strategy backtested, especially as backtest overfitting may occur: when the price of a stock may fit particularly well a given trading strategy over a given period, but not necessarily outside of that period. Besides, backtests do not account for exact market conditions and may yield significantly different results in real trading practice (fees, slippage...).
Furthermore, even though Disfold strives to provide the best and most accurate data, errors can occur in Disfold's systems, or in our data providers' systems.
Please conduct your own due diligence to verify insights.